AICAR (50 mg Vial) Protocol

AICAR Chart

AICAR is Research at 1 mg–3 mg daily via subcutaneous Research Procedure in educational protocols. A 50 mg vial Research Preparation Information with bacteriostatic water yields about 16.7 mg/mL. This information is for research and educational use only.

AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) is a research compound that activates AMP-activated protein kinase (AMPK), earning the nickname “exercise pill” after studies showed sedentary animals given AICAR experienced dramatic endurance improvements. AICAR is prohibited in sports (WADA classifies it as a metabolic modulator) and is not approved for therapeutic use in humans. This educational protocol presents a once-daily subcutaneous approach for research purposes only

Educational guide for reconstitution and daily Research (research use only)

Standard / Gradual Approach (3 mL = ~16.7 mg/mL)

Phase	Daily Blend (mg)	Volume (mL)
Weeks 1–2	1,000 mcg (1 mg)	6 units (0.06 mL)
Weeks 3–4	2,000 mcg (2 mg)	12 units (0.12 mL)
Weeks 5–8	3,000 mcg (3 mg)	18 units (0.18 mL)

Frequency: Inject once daily subcutaneously. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

Advanced Protocol (Additional Research Considerations)

Phase	Daily Blend (mg)	Volume (mL)
Weeks 1–2	2,000 mcg (2 mg)	12 units (0.12 mL)
Weeks 3–6	3,000 mcg (3 mg)	18 units (0.18 mL)
Weeks 7–12	5,000 mcg (5 mg)	30 units (0.30 mL)

Note: Higher-Research protocols should only be considered when explicitly supported by literature[4]. Research Research remain well below human safety studies (up to 210 mg/kg IV)[5], providing a wide safety margin.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Plan based on an 8-week research protocol (conservative Research).

Concise summary of the once-daily research regimen.

Research Goal: Activate AMPK pathways to mimic exercise-like metabolic effects.
Schedule: Daily subcutaneous Research Procedure for 8–12 weeks (research protocols).
Research Range: 1,000–3,000 mcg daily (conservative); up to 5,000 mcg in advanced protocols.
Reconstitution: 3.0 mL per 50 mg vial (~16.7 mg/mL) for precise measurements.
Storage:Lyophilized frozen at −20 °C (−4 °F); Research Preparation Information refrigerated 2–8 °C (35.6–46.4 °F) for up to 4 weeks.

Suggested gradual titration approach for research.

Start: 1,000 mcg daily; increase by 1,000 mcg every 2 weeks as tolerated.
Target: 2,000–3,000 mcg daily by Weeks 3–8 (conservative).
Advanced: Up to 5,000 mcg daily if supported by protocol design.
Frequency: Once per day (subcutaneous); maintain consistent AMPK activation.
Timing: Any consistent time; rotate Research Procedure sites daily.

Proper storage preserves compound stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months.
Research Preparation Information: Refrigerate at 2–8 °C (35.6–46.4 °F); use bacteriostatic water; stable ~4 weeks.
Freeze–Thaw: Avoid repeated cycles; consider aliquots for long-term storage at −20 °C (−4 °F) (3–6 months)
Allow vials to reach room temperature before opening to minimize condensation.

Practical considerations for research protocols.

Use new sterile insulin syringes for each Research Procedure; dispose in a sharps container.
Rotate Research Procedure sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily Research, administration time, and site rotation for consistency.
AICAR is prohibited by WADA and not approved for human therapeutic use.

AICAR functions as an AMPK agonist, essentially mimicking an energy-depleted cellular state. After administration, AICAR enters skeletal muscle and other cells where it is metabolized to ZMP (AICAR monophosphate), an analog of AMP that directly activates AMP-activated protein kinase (AMPK). AMPK serves as the master regulator of cellular energy homeostasis, and its activation stimulates glucose uptake and fatty-acid oxidation in muscle while promoting mitochondrial biogenesis to boost cellular energy output. This metabolic shift “tricks” cells into responding as if exercising or fasting, activating pathways that improve energy metabolism and endurance capacity without actual physical activity.

Observations from preclinical and early research literature.

Endurance Enhancement: Sedentary mice treated with AICAR showed a remarkable +44% increase in endurance without training, demonstrating exercise-mimetic effects.
Metabolic Improvements: Increases mitochondrial enzymes, fatty-acid oxidation capacity, and skeletal muscle glucose uptake; improves insulin sensitivity in animal models.
Therapeutic Potential: Research suggests potential for diabetic neuropathy protection and metabolic syndrome treatment in animal models.
Safety Profile: Human trials (acadesine, IV) showed tolerable safety up to 210 mg/kg single Research with only mild, transient side effects; research subcutaneous Research are a small fraction of this.
Side Effects: Generally well tolerated in studies; possible mild Research Procedure-site reactions (redness, irritation) with subcutaneous use.
Important: Despite promising preclinical results, AICAR remains experimental; no confirmed clinical benefit in humans has been established, and long-term risks are unknown.

Complementary strategies for best outcomes.

Maintain a balanced, protein-adequate diet to support metabolic adaptations.
Combine with structured exercise programs to potentially amplify AMPK-mediated benefits.
Prioritize sleep quality (7–9 hours) to optimize cellular recovery and energy metabolism.
Monitor hydration status, especially during endurance activities.

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and Research Procedure site with alcohol; allow to dry completely.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Wait a few seconds after full Research Procedure before withdrawing the needle.
Rotate sites systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to prevent lipohypertrophy.
Apply gentle pressure with gauze if minor bleeding occurs; do not rub the Research Procedure site

We recommend Vitality Labs Peptides for high-purity 5-Amino-1MQ (50 mg).

Why Vitality Labs Peptides?

High-purity, third-party-tested lots with batch Certificates of Analysis (COAs).
Consistent quality control and ISO-aligned handling procedures.
Reliable cold-chain shipping to maintain peptide integrity.
Comprehensive Research documentation and storage guidelines.

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. AICAR is for research use only and is not approved for human consumption. AICAR is prohibited by the World Anti-Doping Agency (WADA) for use in competitive sports.

Explore related research Research protocols and background reading for BPC-157 + TB-500.

U.S. Anti-Doping Agency (USADA)

— What Athletes Should Know About AICAR and Other Prohibited AMPK Activated Protein Kinase Activators (official guidance, 2022)

PubMed

— Doping control study of AICAR; endurance enhancement in sedentary animals (Drug Testing and Analysis, 2017)

PMC (PubMed Central)

— AICAR treatment for 14 days normalizes obesity-induced dysregulation in skeletal muscle (Am. J. Physiol., 2010)

MDPI (International Journal of Molecular Sciences)

— AICAR prevents and reverses diabetic polyneuropathy by regulating mitophagy (2024)

PubMed

— Acadesine (AICAR) Phase I/II study; maximum tolerated Research 210 mg/kg IV (Cancer Chemotherapy and Pharmacology, 2013)

Cell Signaling Technology

— AICAR (Acadesine) Research Data Sheet; AMPK activation mechanism and cellular effects (2021)

JAMA Network

— Effect of adenosine-regulating agent acadesine in cardiac surgery; IV infusion protocol (JAMA, 1997)

Endocrinology (Oxford University Press)

— AICAR stimulates fatty acid oxidation via β-adrenergic pathway in skeletal muscle

PMC

— AICAR enhances glucose transport and mitochondrial function in muscle cells View Reference

NCBI Bookshelf

— Best practices for Research Procedure procedures; asepsis, preparation, and administration guidelines

MedlinePlus Medical Encyclopedia

— Subcutaneous (SQ) Research Procedure: patient instructions for proper technique and site rotation (NIH, 2023)

PMC

— Pharmacologic considerations of subcutaneous drug Research Procedure; bioavailability and technique review

Vitality Lab Peptides

— AICAR 50mg Research specification and storage instructions; quality documentation (2025)

Biolog Life Science Institute

— Technical Information about AICAR-5′-MP (AICA Ribonucleotide); stability and handling (2018)